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ABSTRACT 
Two human term placentas have been perfused in 
situ with cholesterol-7a-3H. The perfusions were- 
carried out at the time of elective repeat cesarean 
section and tubal ligation in term pregnancies. The 
major tritiated steroid identified was pregnenolone. 
It is suggested that the human placenta has the 
capacity to utilize circulating cholesterol at this 
stage of steroid biogenesis. 
Biosynthetic pathways in most steroid producing 
organs have been found to involve the conversion of 
cholesterol to the various steroid hormones character- 
istic of that organ. In the placenta, the cholesterol 
so utilized has been found to be derived from a series 
of precursors including acetate, mevalonate, squalene, 
and lanosterol (1,2). Placental conversion of 
cholesterol to pregnenolone2) and progesterone in - 
vitro has been demonstrated (3-5). However, in vitro -- 
studies demonstrate the capacity for a reaction to 
occur, without necessarily reflecting the situation 
extant in vivo. Further, the relative contribution 
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of circulating precursors as opposed to de novo _- 
placental synthesis at these stages of steroid bio- 
genesis remains to be ascertained. The present 
study was devised in an effort to assess the capacity 
of the human term placenta to utilize circulating 
cholesterol in steroid biogenesis in vivo, and to 
ascertain the amount of circulating cholesterol 
available to the placenta from both the maternal and 
fetal compartments. 
METHODS AND MATERIALS 
Perfusion Technique: Studies were carried out 
on two patients scheduled for elective repeat cesarean 
section and tubal ligation at term with no other 
medical or obstetric complications of the present 
pregnancy. These studies were performed in a manner 
similar to that previously reported from this 
laboratory for the placental perfusion of labeled 
pregnenolone (6). In brief, after catheterization of 
an umbilical artery and the umbilical vein, whole 
blood was perfused via the umbilical arterial catheter, 
and the venous effluent collected in ethanol. A 50 
percent (v/v) ethanolic solution of cholesterol-7a-3H 
(0.8 ml.) was injected into the umbilical arterial 
catheter at one minute intervals, over a period of 
seven minutes, followed by an additional two minute 
perfusion with blood only. At the conclusion of the 
procedure, the placenta was manually separated from 
the uterus, its membranes and cord dissected free, and 
the placenta was then homogenized in 80% ethanol. 
Materials: All organic solvents were redistilled 
prior to use. Crystalline steroid standards were re- 
crystallized prior to use and corrected melting points 
determined. 
Cholesterol-7cx-3H, Lot. No. 184-32-323) with a 
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Figure 1: Procedures employed in analysis 01 the dichlommethane extract of placenta and venous 
alfluent following h $& brm placental parfusion with cholesteml - 7&- ‘H. 
specific activity (S.A.) of 6.2 mc/mg was purified 
utilizing thin-layer chromatography (TLC) on silica 
gel G4) in the following solvent systems: benzene, 
ethyl acetate, 1-l (Rf = 0.51) and chloroform, acetone 
19:l (Rf = 0.33). Pregnenolone-4-14C, Lot. No. 
79-L39A-83) with a S.A. of 1.4 mc/mg was similarly 
purified in the following solvent systems: cyclohexane, 
ethyl acetate, ethanol, 9:9:2 (Rf = 0.52) and benzene 
ethanol 9:l (Rf = 0.33). The amount of cholesterol- 
701-~H perfused was 16.2 and 24.3 PC. 
Extraction and Purification: This was carried 
out as described previously (6). Briefly, placenta 
and venous effluent were extracted repeatedly with 
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80% and absolute ethanol. This was followed by 
acetone extraction and methanol precipitation at -170~. 
A dichloromethane-water partition was then employed in 
a counter-current fashion, using 6 lower phase transfers, 
and the dichloromethane fraction further analyzed. 
An outline of the procedures employed in the 
analysis of the dichloromethane fraction is illus- 
trated in Figure 1. Twenty-four hour urine specimens 
were collected for three days following the procedure, 
and aliquots of each days urine assessed for their 
radioactive content. 
Countercurrent Distribution (CCD): Twenty-four 
transfer distributions were carried out in a manual 
Craig-Post apparatus using the following solvent 
systems: 
No. 1. Cyclohexane, ethyl acetate, ethanol, 
water (7:3:5:5). 
2. Petroleum ether, methanol, water (10:7:3). 
3. Cyclohexane, ethanol, water (10:9:1). 
4. n-Hexane, ethanol, water (10:4.8:5.2). 
5. Cyclohexane, ethyl acetate, ethanol, 
water (4:1:3:2) 
Derivative formation: Acetylation was carried 
out with acetic anhydride in anhydrous pyridine (1:2) 
at room temperature overnight. Enzymatic deacetylation 
using the enzyme, Acylase5) was performed in the 
following manner: the dried steroid extract was 
dissolved in a drop of ethanol and 1.0 ml. of a 0.1 Molar 
pH 7.3 phosphate buffer. Three mg of the enzyme, 
dissolved in 0.5 ml of the buffer were then added, and 
the solution incubated at 370C for 4 hours. The reaction 
was stopped by the addition of water. 
Thin Layer Chromatoqraphy (TLC): Slurries of 
silica gel G4) were applied to glass plates (5 x 20 cm 
or 20 x 20 cm) and activated at 12OOC. Ascending 
chromatography in the following solvent systems was 
employed: 
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1. Chloroform, acetone (19:l). 
2. Benzene, chloroform (1:l). 
3. Ethyl Acetate, chloroform (5O:l). 
For detection of radioactivity on the 5 x 20 cm 
plates, a Packard Model 7201 radiochromatogram scanner 
was used. 
Estimation of C-21 Steroids: Progesterone was 
measured in ethanol by ultraviolet absorption at 
240 rnv using the Allen correction formula (7). For 
detection of pregnenolone on thin-layer chromatograms 
either a phosphomolybdic acid or water spray was 
employed. Progesterone was detected on thin layer 
chromatograms with ultraviolet light. Measurement 
of 3p-hydroxy-A5 steroids was carried out as described 
by Oertel and Eik-Nes (8). 
Cholesterol Determinations: Total and esterified 
cholesterol were measured in serum utilizing the 
methods described by Connerty et al. (9, 10). 
Recrystallization to Constant Specific Activity: 
Crystalline pregnenolone acetate was added to part of 
the isolated radioactive material obtained from the 
third CCD. Successive recrystallizations from three 
different solvent systems were performed. The carrier 
was estimated gravimetrically. 
Countinq Procedure: Counting was carried out in 
an automated two channel Packard Tri-Carb liquid 
scintillation counter (series 3000). The tritium 
window was set from 10 to 100% of the analyzer full 
scale with a relative gain of 60, and the carbon 
window was set from 10 to 70% of full scale with a 
relative gain of 5. Samples were counted in 10 ml 
toluene containing 3.0 g/l PPO (2,5-diphenyloxazole) 
and 100 mg/l POPOP (1, 4-bis-2-(4-methyl-5-phenyl- 
oxazolyl) benzene). Urine samples (0.5 ml) were first 
dissolved in one ml methanol and then 10 ml of the 
above toluene scintillant solution added. Appropriate 
quench corrections were made using an internal 
standard technique. Counting efficiencies were 
monitored utilizing standards prepared in the same 
manner as the samples. 
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RESULTS 
The bulk of the converted radioactive material 
in the "free" (dichloromethane-soluble) fraction in 
both placenta and venous effluent was identified as 
pregnenolone. This amounted to 49 and 70% of the free 
radioactive material recovered from the placenta and 
14 and 49% of that in the venous effluent. The bulk 
of the remaining radioactive material was unchanged 
cholesterol. The cholesterol-like material from 
the first CCD was acetylated, and further characterized 
by TLC in Systems 1 and 2. There was good agreement 
between the Rf of authentic cholesterol acetate and 
that of the acetylated radioactive material in both 
TLC systems. 
In Experiment 1, the tritiated progesterone-like 
material was characterized in CCD Systems 1, 2, 4 
and 5 and in TLC System 3. Excellent agreement was 
noted between partition coefficients and the Rf value 
of carrier progesterone and the tritiated material. 
The quantity of radioactive material associated with 
carrier progesterone was insufficient to permit 
further identification. In Experiment 2, there was 
no appreciable radioactivity associated with the 
carrier progesterone. 
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As noted in Figure 1, the identification of 
pregnenolone was based on an initial CCD as the free 
compound. The pregnenolone-like material was then 
acetylated and two CCD's of the acetate of pregnenolone 
carried out. Figure 2 illustrates a representative 
countercurrent distribution curve obtained in CCD 
System 3, immediately prior to recrystallization. 
The lower curve is that of authentic "carrier" 
pregnenolone acetate-4-14 C, the free form having been 
added at the initiation of the processing of the 
dichloromethane extract. The upper curve, with an 
identical partition coefficient (K = 0.82), is that 
of the tritiated material derived from the perfusion. 
Following the third CCD, an aliquot of the 
radioactive material was mixed with crystalline 
pregnenolone-acetate carrier, and recrystallized to 
constant S.A. The recrystallization data are presented 
in Table 1. Insufficient radioactive material pre- 
cluded recrystallization in the venous effluent of 
Experiment 2. 
An additional aliquot of the radioactive 
pregnenolone acetate-like material was deacetylated, 
and a final countercurrent distribution in System 
4 performed. Again, there was excellent agreement 
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III situ perruslon ot human term placenta with Cholesterol-7a-=H. Carrier 
steroid is preqnenolone acetate-4-l*C. 
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Recrystallization Data (c.p.m./mq.) of preqnenolone (as acetate) derived from 
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a) Insufficient radioactive material precluded recrystallization of 
pregnenolone acetate in the venou.s effluent of Exp. 2 
b) c = crystal ML = Mother Liquor 
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between carrier and tritiated material. Recovery of 
radioactive material in these experiments was very 
low; in the 2 experiments, 0.2 and 0.9 percent of 
the injected radioactivity were recovered as 
pregnenolone in the placenta and venous effluent. 
As expected, since very little cholesterol is 
excreted in the urine, there was no significant 
radioactivity measured in the small urinary aliquots 
(0.5 ml) taken for counting. Analysis of large pools 
of maternal urine for steroid content was not under- 
taken. 
To assess the extent to which cholesterol is 
available for placental utilization in both the 
maternal and fetal compartments, in 40 term pregnancies 
terminated by vaginal delivery, the concentration of 
total and esterified cholesterol was determined in 
umbilical venous blood. In twelve of these, umbilical 
arterial samples were also obtained. In addition, 
cholesterol levels were measured in maternal ante- 
cubital vein blood in 19 cases. In the umbilical 
artery, the mean concentration of total cholesterol 
was 88 mg/lOO ml serum (range 52-142) and in the vein 
it was 74 mg/lOO ml (range 44-137). The mean esterified 
cholesterol fraction in the umbilical artery was 79 
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percent, and that in the vein was 77 percent. When 
paired samples were considered, arterio-venous differ- 
ences were not statistically significant. In the 
maternal venous blood, the mean total cholesterol 
was 196 mg/lOO ml (range 110-290) with 63 percent 
esterified. 
DISCUSSION 
It is becoming increasingly apparent that blood- 
borne precursors, reaching the placenta from the 
maternal and/or fetal compartments may be utilized in 
the placental elaboration of certain estrogens (11-15). 
That circulating precursors, at least from the fetal 
compartment, are necessary for the placental production 
of progesterone seems less certain for reasons detailed 
in earlier communications (6, 16). 
In addition, as noted previously, in vitro placental _- 
conversion of acetate and mevalonate to lanosterol and 
cholesterol has been demonstrated (1, 2). Further, 
incubation of mitochondrial preparations of human 
term placentas with labeled cholesterol and a TPNH 
generating system by Morrison et al. (5) gave rise to 
both pregnenolone and progesterone, the latter in high 
yield. An in vitro perfusion study by Solomon (3) also -- 
demonstrated this conversion, although in low yield. 
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However, as has been demonstrated recently in vivo -- 
by Jaffe and Ledger (6) the human term placenta is 
capable of utilizing circulating pregnenolone in the 
production of progesterone. And it effects this 
conversion in a rapid and efficient manner. Circulating 
pregnenolone sulfate is similarly metabolized (17, 18). 
With the relatively large quantities of cholesterol in 
both the maternal and fetal circulation, it was of 
interest to ascertain whether the placenta was also 
capable of utilizing circulating cholesterol in 
steroidogenesis; the presently described experiments 
demonstrate this capacity to be present and suggest 
that circulating cholesterol may contribute at least 
some of the starting material for placental steroid 
synthesis. To assess the capacity of placental 
transfer of maternal cholesterol, experiments are 
now in progress in which tritiated cholesterol 
preincubated with maternal serum (19), has been 
injected into the maternal circulation and a search 
made for pregnenolone and progesterone metabolites. 
The utilization of circulating cholesterol in 
adrenocortical steroid synthesis in the non-pregnant 
individual has been demonstrated (20). Bloch's 
classic work (21) also demonstrated the conversion, 
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in pregnancy, of orally administered deuterium 
labeled cholesterol to deuterium labeled pregnanediol. 
Under the conditions employed in the presently 
described experiments, the bulk of the converted 
radioactive material was found to be pregnenolone, 
with progesterone being detected in small quantities 
in one experiment. In view of the relative efficiency 
of placental conversion of pregnenolone to progesterone 
(6), the reason for the failure to demonstrate larger 
amounts of progesterone is not immediately apparent. 
A similar finding was noted upon perfusion of a 
midtrimester placenta with cholesterol (22). 
That circulating cholesterol is available to the 
placenta both from the maternal and fetal side is 
apparent from the concentration of plasma cholesterol 
in these two compartments. 
The mean umbilical venous cholesterol values agree 
closely with those of Mortimer (23), Rafstedt (24) and 
Lloyd (25), and are slightly higher than those of 
Brody and Carlson (26). The authors are unaware of 
other studies of paired umbilical arterial and venous 
samples. The concentration of cholesterol in the 
maternal compartment has been found to increase from 
the second trimester to term (27). This increase is 
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present in both the free and esterified fractions. 
The values obtained in this study are somewhat lower 
than those found by de Alvarez et al. (27). Sample 
size in the present study was small, and it is known 
that there is wide variation in maternal cholesterol 
levels. 
Circulating cholesteryl sulfate has been found 
in human plasma (28) and umbilical cord blood (29). 
Whether it is utilized in placental steroidogenesis 
remains to be ascertained. 
It should be noted that while extraction 
procedures for both placenta and venous effluent 
were essentially the same as those employed for 
evaluation of other steroid precursors, both 
phenolic (30) and neutral (6, 16), under similar 
experimental conditions, recoveries were far less 
complete when cholesterol was perfused. This may be 
a reflection of either solubilization factors, 
membrane permeability, precipitation of sterols with 
methanol, rapid passage across the placenta or the 
ubiquitous pathways of cholesterol metabolism in the 
placenta, only the steroid fraction being extracted 
by our techniques. Experiments are being undertaken 
involving placental perfusion of tritiated cholesterol 
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preincubated with serum (19) in an attempt to increase 
recovery and more closely approximate the physiologic 
situation. It is felt that this reaction may be of 
importance, in spite of these low recoveries, since 
even a low rate of conversion might explain a significant 
amount of the placental steroid elaboration extant in 
pregnancy. 
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